Rezolute Inc
RZLT9.100USD
-0.220-2.36%
收盤 11/03, 16:00（美東）報價延遲15分鐘
791.66M總市值
虧損本益比TTM
關於 Rezolute Inc 公司
Rezolute, Inc. 是一家後期罕見病公司，專注於改善因高胰島素血癥 (HI) 引起的低血糖症患者的治療效果。其主要臨牀資產 Ersodetug（原名 RZ358）是一種潛在的治療由多種形式的高胰島素血癥引起的低血糖症的方法，包括先天性 HI 和腫瘤性 HI。Ersodetug 是一種靜脈注射的人類單克隆抗體，可與胰島素靶組織（例如肝臟、脂肪和肌肉）中胰島素受體上的獨特位點（變構）結合。先天性是一種罕見的兒科遺傳性疾病，其特徵是胰腺過量產生胰島素。RZ402 是一種口服血漿激肽釋放酶抑制劑 (PKI)，正在開發作爲糖尿病性黃斑水腫 (DME) 慢性治療的潛在療法。DME 是糖尿病的血管併發症，也是失明的主要原因。RZ402 旨在阻止緩激肽的產生及其對血管滲漏和炎症的影響。
Rezolute Inc簡介
公司代碼RZLT
公司名稱Rezolute Inc
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
員工數量59
證券類型Ordinary Share
年結日Dec 23
公司地址275 Shoreline Drive, Suite 500
城市REDWOOD CITY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編94065
電話16502064507
網址https://www.rezolutebio.com/
公司代碼RZLT
上市日期Dec 23, 2011
CEOMr. Nevan Charles Elam, J.D.
Rezolute Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
115.45K
-23.01%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
58.52K
-37.09%
Dr. Sunil Karnawat
Dr. Sunil Karnawat
Chief Commercial Officer
Chief Commercial Officer
12.34K
-55.03%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
3.08K
-91.81%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
--
-100.00%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
Mr. Daron Evans
Mr. Daron Evans
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Mr. Gilbert M. (Gil) Labrucherie, J.D.
Independent Director
Independent Director
--
--
Dr. Brian K. Roberts, M.D.
Dr. Brian K. Roberts, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Erik Harris
Mr. Erik Harris
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Young-Jin Kim
Mr. Young-Jin Kim
Director
Director
115.45K
-23.01%
Dr. Wladimir Hogenhuis, M.D.
Dr. Wladimir Hogenhuis, M.D.
Independent Director
Independent Director
58.52K
-37.09%
Dr. Sunil Karnawat
Dr. Sunil Karnawat
Chief Commercial Officer
Chief Commercial Officer
12.34K
-55.03%
Dr. Nerissa C. Kreher, M.D.
Dr. Nerissa C. Kreher, M.D.
Independent Director
Independent Director
3.08K
-91.81%
Mr. Philippe Fauchet
Mr. Philippe Fauchet
Independent Director
Independent Director
--
-100.00%
Mr. Nevan Charles Elam, J.D.
Mr. Nevan Charles Elam, J.D.
Acting Chairman of the Board, Chief Executive Officer
Acting Chairman of the Board, Chief Executive Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月26日 週五
更新時間: 9月26日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
15.45%
Fidelity Management & Research Company LLC
13.74%
Handok Inc
9.27%
Invus Public Equities LP
5.36%
The Vanguard Group, Inc.
4.43%
其他
51.75%
持股股東
持股股東
佔比
Federated Hermes Global Investment Management Corp.
15.45%
Fidelity Management & Research Company LLC
13.74%
Handok Inc
9.27%
Invus Public Equities LP
5.36%
The Vanguard Group, Inc.
4.43%
其他
51.75%
股東類型
持股股東
佔比
Investment Advisor
34.32%
Investment Advisor/Hedge Fund
29.11%
Hedge Fund
25.42%
Corporation
9.27%
Venture Capital
2.42%
Research Firm
0.86%
Individual Investor
0.65%
Bank and Trust
0.08%
Pension Fund
0.05%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
198
83.92M
92.40%
+29.30M
2025Q2
154
54.05M
62.26%
-7.68M
2025Q1
149
54.85M
64.71%
-11.78M
2024Q4
130
52.42M
86.65%
+2.62M
2024Q3
103
45.09M
85.49%
-8.77M
2024Q2
88
47.89M
96.58%
+4.94M
2024Q1
69
35.39M
87.04%
-8.22M
2023Q4
65
37.08M
93.56%
-2.65M
2023Q3
67
32.22M
86.09%
-5.29M
2023Q2
66
32.97M
88.12%
-2.31M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Federated Hermes Global Investment Management Corp.
14.03M
15.45%
+2.76M
+24.43%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.48M
13.74%
+6.19M
+98.42%
Jun 30, 2025
Handok Inc
8.42M
9.28%
+1.23M
+17.11%
Sep 22, 2025
Invus Public Equities LP
4.87M
5.36%
+4.87M
--
Sep 18, 2025
The Vanguard Group, Inc.
4.02M
4.43%
+1.65M
+69.34%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.73M
4.11%
+3.34M
+857.33%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
3.56M
3.92%
+1.82M
+104.06%
Jun 30, 2025
UBS Financial Services, Inc.
3.04M
3.34%
+2.42M
+392.63%
Jun 30, 2025
Great Point Partners, LLC
3.03M
3.34%
+2.20M
+264.14%
Jun 30, 2025
Marshall Wace LLP
2.89M
3.18%
+1.04M
+56.43%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
ALPS Medical Breakthroughs ETF
0.5%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Even Herd Long Short ETF
0.28%
Fidelity Fundamental Small-Mid Cap ETF
0.21%
iShares Micro-Cap ETF
0.15%
SPDR S&P Biotech ETF
0.13%
Vanguard US Momentum Factor ETF
0.07%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
iShares Russell 2000 Growth ETF
0.04%
ProShares Hedge Replication ETF
0.03%
查看更多
ALPS Medical Breakthroughs ETF
佔比0.5%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.44%
Even Herd Long Short ETF
佔比0.28%
Fidelity Fundamental Small-Mid Cap ETF
佔比0.21%
iShares Micro-Cap ETF
佔比0.15%
SPDR S&P Biotech ETF
佔比0.13%
Vanguard US Momentum Factor ETF
佔比0.07%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.07%
iShares Russell 2000 Growth ETF
佔比0.04%
ProShares Hedge Replication ETF
佔比0.03%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
